Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicaid Best Price Reform: Dual-Eligible Move To Medicare May Be 1st Step

Executive Summary

The effect of moving 60% of the prescriptions covered by Medicaid into Medicare is one issue being considered by the Medicare prescription drug conference committee as it determines how to handle "dual-eligibles.

You may also be interested in...



Medicaid Cost-Containment Strategies May Include PDL For Antipsychotics

Implementing preferred drug lists for mental health drugs may be one cost-containment strategy used by states as they seek to blunt the shift of "dual eligibles" to Medicare

Medicaid Cost-Containment Strategies May Include PDL For Antipsychotics

Implementing preferred drug lists for mental health drugs may be one cost-containment strategy used by states as they seek to blunt the shift of "dual eligibles" to Medicare

Maine Medicaid May Use Medicare To Enhance Price Power: PDP Meets PDL

State Medicaid agencies are considering ways to use the upcoming Medicare prescription drug coverage program to enhance their drug price negotiating power

Related Content

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel